A Digital Awakening in Europe’s Peptide Industry

Europe’s peptide makers embrace digital tools to boost quality and speed as demand for next generation therapies surges

9 Jan 2026

Europe’s therapeutic peptide manufacturers are increasing investment in digital systems and automated processes as rising demand for obesity, cancer and rare disease treatments tests existing production models.

Peptide medicines have moved into the mainstream in recent years, prompting companies to reassess how these complex drugs are made. Industry executives and analysts say digital tools are becoming central to improving scale, quality and long-term competitiveness.

Production has historically relied on manual documentation and older factory systems. While workable at small volumes, such methods can create bottlenecks as output rises. Analysts note that peptide and active pharmaceutical ingredient manufacturing has lagged other parts of the drug industry in adopting modern digital infrastructure, despite facing similar regulatory standards.

Across the wider pharmaceutical sector, tools such as electronic batch records, automated manufacturing execution systems and real-time monitoring are now common. These systems are designed to reduce manual errors, strengthen compliance and improve efficiency. Adoption in peptide manufacturing, however, remains uneven.

The shift is influencing strategy across Europe’s supply chain. Manufacturers and contract development and manufacturing organisations (CDMOs) are expanding capacity while updating workflows to improve oversight and respond more quickly to quality deviations.

Groups including Bachem have stressed the importance of efficient, high-quality production as demand increases. CDMOs such as CordenPharma are investing heavily in new facilities, where digital systems are expected to support future competitiveness.

Technology providers are also positioning themselves for growth. Companies such as Siemens offer automation platforms tailored to regulated pharmaceutical environments, aiming to deliver more consistent batches and shorter production cycles while strengthening data collection.

The push towards digitalisation aligns with broader European efforts to reinforce the region’s role in advanced therapeutics manufacturing. Policymakers have highlighted supply resilience as global competition intensifies.

Modernisation, however, requires significant capital and careful validation. Many facilities still operate with legacy infrastructure, and digital rollouts demand staff training and regulatory approval.

Even so, companies across the sector appear committed to gradual upgrades, betting that more automated and data-driven production will underpin reliability and expansion in the years ahead.